A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Brief description of study

The primary purpose of the study is to determine if a reduced dose of radiation to the whole brain and spine and less chemotherapy can be given to children and young adults with WNT-subgroup MB (medulloblastoma) without increasing the risk of the tumor coming back. During the study, we also want to know how the treatment will affect thinking and learning. The combination of a reduction in radiation therapy and chemotherapy is experimental.

Clinical Study Identifier: s18-01769

ClinicalTrials.gov Identifier: NCT02724579

Principal Investigator: Mark E Weinblatt.

Other Investigators: Christeen Azmy, Chana Glasser, William M Gerba, Sucharita Bhaumik, Philip G Scimeca.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies